首页> 外文期刊>Progres en urologie: journal de l’Association francaise d’urologie et de la Societefrancaise d’urologie >Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer [Recommandations du comité de cancérologie de l'Association fran?aise d'urologie (CC-AFU) pour la bonne pratique des instillations endovésicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n'envahissant pas le muscle (TVNIM)]
【24h】

Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer [Recommandations du comité de cancérologie de l'Association fran?aise d'urologie (CC-AFU) pour la bonne pratique des instillations endovésicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n'envahissant pas le muscle (TVNIM)]

机译:法国国家癌症委员会(CC-AFU)针对非肌肉浸润性膀胱癌的BCG和丝裂霉素C膀胱内滴注良好操作规范指南。 )进行卡介苗卡介苗和肌霉素C膀胱内滴注治疗不侵犯肌肉的膀胱肿瘤(TVNIM)的良好做法]

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Intravesical BCG immunotherapy and mitomycin C are considered as the standard treatment for non-muscle invasive bladder cancer. These guidelines aim to describe the optimal condition to perform intravesical instillation of BCG or mitomycin C in order to increase its oncologic efficiency and to decrease its morbidity. Methods: Online systematic literature search was performed on PubMed ? until April 2010. Regulation texts, published guidelines and results of recent urologists practice study were taken into consideration. Level of evidence was assigned to each recommendation. A bibliographic research in French and English using Medline ? and Embase ? with the keywords "BCG", "mitomycin C", "bladder", "complication", "toxicity", "adverse reaction", "prevention" and "treatment" was performed. Results: Patient information must be prior to the first intravesical instillation and should be given through a medical exam by the physician performing the procedure. The check for formal contra-indication to BCG is systematically mandatory by the physician during the medical exam. Intravesical instillation must be realized in a health center where urologic endoscopic procedures are made frequently. A recent urine culture has to be checked systematically before any instillation done either by the urologist or a specialized nurse. Contingent upon a bladder catheter has been inserted in the bladder without any injury of the lower urinary tract, the instillation can be done. The pharmaceutical agent needs to be kept two hours in the bladder. After instillation, the patient must be seated to void and also has to keep in mind that he needs to drink at least 2 liters of water per day for 2 days. Conclusion: To improve the oncologic performance and to reduce the risk of complication and adverse event, achievement of intravesical instillations of BCG and/or mitomycin C should follow a standardized procedure.
机译:简介:膀胱内BCG免疫疗法和丝裂霉素C被视为非肌肉浸润性膀胱癌的标准治疗方法。这些指南旨在描述进行BCG或丝裂霉素C膀胱内滴注的最佳条件,以提高其肿瘤学效率并降低其发病率。方法:在PubMed?上进行在线系统文献检索。直到2010年4月为止。法规文本,已发布的指南和最近泌尿科医师实践研究的结果已得到考虑。证据级别分配给每个建议。使用Medline的法文和英文书目研究?和Embase?使用关键词“ BCG”,“丝裂霉素C”,“膀胱”,“并发症”,“毒性”,“不良反应”,“预防”和“治疗”。结果:患者信息必须在首次膀胱内滴注之前进行,并应由执行该过程的医师通过体检给出。在体格检查期间,医师会系统地强制性检查BCG的正式禁忌症。膀胱内滴注必须在经常进行泌尿外科内窥镜检查的医疗中心进行。在泌尿科医师或专职护士进行任何滴注之前,必须系统地检查最近的尿液培养情况。视膀胱导管是否已插入膀胱而没有下泌尿道的任何损伤而定,可以进行滴注。药物需要在膀胱中放置两个小时。滴注后,患者必须坐到空隙,并且还必须记住,他需要每天至少喝2升水,持续2天。结论:为了提高肿瘤学性能并降低并发症和不良事件的风险,应遵循标准化程序进行BCG和/或丝裂霉素C膀胱内滴注。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号